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Abstract. Background: (–)-Epicatechin (EC) is a naturally
occurring compound which induces oxidative DNA damage
in human acute myeloid leukaemia (AML) cells. Aim: The
aim of the study was to examine the influence of EC on the
antileukaemic effect of etoposide in rats with AML. Materials
and Methods: Brown Norway rats with AML were treated
with EC for 23 days and etoposide was administered for the
last three days of the experiment. Bone marrow and splenic
cell apoptosis was investigated by flow cytometry using
annexin V-allophycocyanin staining. The oxidative status was
investigated in homogenates of the liver. Results: EC was
found to increase the in vivo apoptotic effect of etoposide
resulting in the decrease of the percentage of leukaemia cells
in EC-treated rats in comparison to those treated with
etoposide only. Investigation of malondialdehyde and ferric
ion-reducing ability of plasma levels indicated that EC
increases the oxidative stress induced by etoposide in
leukaemic rats. Conclusion: EC can enhance the
antileukaemia properties of etoposide in vivo through
augmentation of oxidative stress.
Acute myeloid leukaemia (AML) accounts for 80% of all
acute leukaemia cases in adult humans (1). In developed
countries, AML occurs with a frequency of 1/100,000, and
the number of cases is increasing every year (2). Despite
immense steps forward in studies on the pathomechanism of
the disease, identification of new prognostic factors and
modification of treatment protocols (3, 4), AML remains a
disease which is difficult to cure. Chemotherapeutic
treatment in individuals below 60 years of age usually results
in complete remission; however, in the majority of the
patients, it eventually leads to recurrence of the disease and
death (5). In patients over 60 years of age, the results of the
treatment are much worse (5). Therefore, ways to increase
therapeutic index of this disease are still being sought. 
New compounds which can be used in future targeted
AML therapy or complementary treatment to enhance the
effect of conventional anticancer drugs are being
extensively studied (6, 7). Plant polyphenols are among the
compounds which arouse interest in this field. These
compounds are known for selective, cytotoxic effect against
cancer cells and relatively low toxicity towards normal cells
(8, 9). Polyphenols from the catechin group, such as (−)-
epigallocatechin (EGC), (−)-epigallocatechin-3-gallate
(EGCG) have been shown to be cytotoxic to AML cells
(10). These two catechins inhibited the growth and induced
apoptosis of human promyelocytic leukaemia HL-60 cells
by reducing the levels of B-cell lymphoma 2 (BCL-2)
protein and activation of caspase-3 (10). EGCG also
induced necrosis-like cell death of chronic myeloid
leukaemia K562 cells and in this way it overcome apoptosis
resistance (11). 
The generation of highly toxic radicals seems to play an
important role in the cytotoxic action of EGCG in leukaemia
cells derived from myeloid precursors with a high
constitutive activity of myeloperoxidase (MPO) (12, 13).
Nakazato et al. (13) demonstrated that EGCG increases
oxidative stress in AML cells and in the HL-60 cell line
derived from the human acute promyelocytic leukaemia,
using the MPO/H2O2/halide system. 
Recently, it was demonstrated that catechin hydrate,
another component of green tea, exerted a dose-dependent
apoptotic effect in breast cancer MCF-7 and cervical
carcinoma SiHa cells by inducing expression of proapoptotic
genes (14). Most studies on the anticancer effects of
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catechins focused on EGCG, the most active component of
green tea. However, in vivo research on the anticancer
activity of (–)-epicatechin (EC), which is characterized as
having the best bioavailability among other green tea
catechins, is very limited (15).
In our previous studies, EC administered orally at a high
dose of 40 mg/kg b.w. (non-cytotoxic) for 23 days,
demonstrated antileukaemic activity in a rat model of AML
in vivo. This polyphenol induces apoptosis of leukaemia
cells, leading to a decrease in their number in the spleen of
the sick animals (16). However, Oikawa et al. (17) proved
that EC undergoes MPO-catalyzed one-electron oxidation
and induces oxidative DNA damage in HL-60 cells, by the
increase of intracellular production of H2O2.
One of the cytostatic drugs used in AML treatment is
etoposide which, similarly to EC, undergoes one-electron
oxidation catalyzed by MPO (18). The mechanism of
anticancer activity of the etoposide is based on inhibition of
the topoisomerase II-DNA cleavable complex, which leads
to the formation of DNA strand breaks and to apoptosis of
cancer cells (19). This drug is used in a wide-spectrum
treatment of both solid tumors and leukaemias, but the effect
of its genotoxicity is especially pronounced in myeloid
precursors with high MPO activity (18). 
Etoposide phenoxyl radicals formed by MPO may
enhance the genotoxic effects of etoposide in these cells (18).
In addition, MPO converts etoposide to O-demethylated
metabolites, such as catechol and quinone, which possess
much stronger pro-oxidant activities than etoposide and
influence topoisomerase II activity with similar strength as
this cytostatic (20, 21).
Taking into account that more free radicals usually arise
in cancer cells than in normal cells (22), it can be supposed
that EC will enhance etoposide activity in leukaemia cells
more than in their normal counterparts. 
The aim of this study was to determine whether EC
modifies etoposide activity in bone marrow and spleen cells
in rats with promyelocytic leukaemia.
Materials and Methods
Chemicals. Reagents including EC, propidium iodide (PI), red blood
cell lysing buffer with ammonium chloride, polyethylene glycol,
polysorbate 80, benzyl alcohol, citric acid, ethanol and all reagents
used in ferric ion reducing ability of plasma (FRAP),
malondialdehyde (MDA) and superoxide dismutase (SOD)
investigation were obtained from Sigma–Aldrich Co. (St. Louis,
MO, USA). VEPESID (etoposide) was purchased from Bristol-
Myers Squibb S.p.A. (Sermoneta, Italy). RPMI 1640 medium, fetal
bovine serum (FBS) and phosphate-buffered saline (PBS) were
purchased from PAA (Pasching, Austria). Fluorescein isothiocyanate
(FITC)-conjugated mouse anti-rat CD45R monoclonal antibody,
annexin-V-allophycocyanin (APC) and 7-aminoactinomycin D (7-
AAD) were obtained from BD Biosciences Pharmingen (San Diego,
CA, USA). (PE)-conjugated goat anti-mouse antibody specific
against μ chain was acquired from Jackson ImmunoResearch
Laboratories (West Grove, PA, USA). 
Animals. Male Brown Norway (BN/CrlCmd) rats (297.2±3.6 g)
were obtained from the Animal Center, Polish Academy of Sciences
Medical Research Center (Warsaw, Poland). The animals were
housed in plastic cages and kept under standard conditions of 22˚C
and 50-60% humidity, with a 12-h light-dark cycle. They were fed
a synthetic pellet diet (Morawski Label Feed, Kcynia, Poland) and
had free access to water. 
BN rat myeloid leukaemia model. BN rats with acute myeloid
leukaemia (BNML) are regarded as one of the best animal models
of myeloid leukaemia due to their many similarities to human AML,
e.g. growth pattern (23). In this experimental model, leukaemia is
transplantable and BNML cells are inoculated into immunologically
competent rats. In the present study, BNML was developed after
intravenous inoculation with 106 spleen-derived leukaemia cells
(kindly provided by Professor A.C.M. Martens, Utrecht University,
the Netherlands) in PBS. Experiments were performed in
accordance with legal requirements, under a licence granted by the
Jagiellonian University Ethical Committee.
Treatment protocol. The doses of EC (20 and 40 mg/kg b.w.) were
chosen based on our previous research in which EC at a dose of
40 mg/kg b.w. significantly increased apoptosis, while a lower
dose (20 mg/kg b.w.) did not induce such an effect on BNML
cells of leukaemic rats (16). EC was dissolved in hot water and,
after cooling, was administered by oral gavage (40 mg/kg b.w. in
0.5 ml of water) from the second day after the inoculation of
BNML cells, every 24 hours until day 23 of leukaemia
development. In the study, 50 mg of etoposide/kg b.w. of rat was
used, which induced severe DNA damage in the bone marrow of
healthy mice (24). Etoposide was administered every 24 hours for
three consecutive days starting on the 21st day of leukaemia
development. Etoposide was administered intraperitoneally to
avoid possible influence of EC on its intestinal bioavailability.
Control rats were administered with solvents of investigated
compounds. Six to eight leukemic rats were included in each
group. Six healthy control and EC-treated rats were also used to
investigate the influence of EC on the oxidative status. These rats
were killed 1.5 hour after etoposide and 2 hours after EC
administration. Turner et al. (24) observed the greatest DNA
damage in the bone marrow of mice one hour after peritoneal
administration of etoposide. Behaviour, weight and general
condition of the animals were monitored. 
Organ excision and cell isolation. Rats were killed by cervical
dislocation under vetbutal anaesthesia. The right femurs were
removed and the bone marrow was used for the preparation of
smears using a small paintbrush. Bone marrow from left femurs was
flushed with 1 ml FBS and then washed once in PBS (230 ×g, 10
min, 4˚C). Spleens were excised, weighed and macerated into a
Petri dish filled with RPMI-1640 medium, and subsequently
centrifuged (230 ×g, 10 min, 4˚C). Livers were excised,
immediately frozen and stored at −80˚C until redox state
investigation. In order to examine cells by flow cytometry, the
isolated cells were counted in a Bürker haemocytometer and
erythrocytes were lysed with red blood cell-lysing buffer containing
0.83% ammonium chloride in 0.01 M Tris buffer (pH 7.5). 
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Cytological study of bone marrow. Smears were stained using May-
Grünwald-Giemsa stain and examined by counting approximately
500 cells/slides on three slides from each animal using an Olympus
CX-40 microscope (Olympus, Tokyo, Japan). 
Detection of BNML cells and analysis of apoptotic and necrotic cell
death. Isolated cells (1×106) were incubated for 45 min on ice in
100-μl PBS containing 5% FBS and 10% mouse primary
monoclonal anti-RM124 antibody (kindly provided by Professor
A.C.M. Martens), which recognises the specific epitope of the
leukaemia cells (23). After incubation, the cells were washed in PBS
(230 ×g, 10 min, 4˚C). Next, they were incubated with secondary
goat anti-mouse monoclonal antibody conjugated to R-PE for 30
min and washed in PBS (230 ×g, 10 min, 4˚C). The cells were than
incubated with FITC-conjugated mouse anti-rat CD45R monoclonal
antibody for 20 min to evaluate the nonspecific binding of the
secondary antibody to B-lymphocytes. Subsequently, the cells were
stained with annexin V-APC (An-APC) and 7AAD according to the
instructions provided by the manufacturer and incubated in the dark
for 15 min. All the steps were performed on ice. The cells were
analyzed using a FACSCalibur flow cytometer and CellQuest
software (BD Biosciences Immunocytometry Systems, San Jose,
CA, USA). Apoptotic cells were defined as APC-An-positive and
7AAD-negative, while necrotic and/or late apoptotic cells were
APC-An- and 7AAD-positive, necrotic cells were 7AAD-positive
and APC-An-negative. Results were expressed as the percentage of
apoptotic or necrotic cells. 
Measurement of FRAP. The method of Benzie and Strain (25) was
used to determine FRAP as an indicator of the antioxidant content.
FRAP values were obtained by measuring ferric to ferrous ion
reduction at low pH (300 mmol acetate buffer, pH 3.6), coupled
with tripyridyltriazine, a blue-colored complex, whose absorbance
was measured at 593 nm. Tissues were homogenized in 0.05 M
phosphate buffer (pH 7.8) to 10% final concentration. Homogenized
tissues were centrifuged at 1000 ×g for 15 min (0-4˚C). The
supernatant was drawn and the pellet was discarded. Each sample
(0.1 ml) was mixed with 3 ml reagent mixture [30 ml, consisting of
25 ml of acetate buffer (300 mM; pH 3.6), 2.5 ml 2,4,6-Tris(2-
pyridyl)-S-triazine (5 mM TPTZ) in 40 mM HCl, and 2.5 ml ferric
solution (20 mM FeCl3) in distilled water]. The FRAP was
calculated by preparing a standard curve between 0 and 1 mM of
known Fe2+ sample using FeSO4•7H2O as the standard. The blank
contained FRAP reagent mixture. Reactions were performed for 
5 min at 37˚C and analyzed spectrophotometrically. FRAP values
are expressed as μmol/mg of protein. 
Investigation of lipid peroxidation. The concentration of MDA, a
product of lipid peroxidation, was measured in liver homogenates
according to the method of Buege and Aust (26), based on
thiobarbituric acid (TBA) reactivity. Reaction of MDA with TBA
followed by measurement of the pink chromophore product was used
for quantitative determination of MDA. Each sample (0.5 ml) was
mixed with 1.5 ml reagent mixture (TBA/TCA/HCl reagent by
diluting the stock solution 4-fold in water) to maintain a
reagent/sample ratio of 2:1 (v/v). Working solution was prepared by
diluting the stock solution of TBA/TCA/HCl 4-fold in water.
Butylated hydroxytoluene (BHT) in ethanol was added to a final
concentration of 0.03%. After shaking the tube, the mixture was
placed into boiling water bath for 15 min. After cooling in cold
water, the obtained chromogen was extracted with 3.0-ml n-butyl
alcohol by vigorous shaking for 1 min. Separation of the organic
phase was facilitated by centrifugation at 1000 ×g for 10 min. The
TBA-MDA adduct was quantified using fluorescence emission at 553
nm upon assessment of cell toxicity excitation at 532 nm. The MDA
concentration was measured by preparing a standard curve between
0 and 50 nmol MDA/sample using 1,1,3,3-tetramethoxypropane as
the standard. MDA concentrations are expressed as nmol/mg of
protein. The measurements were performed by using a
spectrofluorometer (Perkin Elmer LS-5, USA). 
Measurements of SOD activity. SOD activity was investigated by the
method of Spitz and Oberley (27) in homogenates from liver.
Xanthine–xanthine oxidase was utilized to generate a superoxide flux.
Nitro-blue tetrazolium (NBT) reduction by O2•− to blue formazan was
followed at 560 nm in a Marcel Media (Poland) spectrophotometer
at room temperature. The rate of NBT reduction in the absence of
tissue was used as the reference rate (0.020±0.005 AU/min). When
increasing amounts of protein (containing SOD activity) were added
to the system, the NBT reduction rate was progressively inhibited.
The amount of inhibition was defined as a percentage of the reference
rate of NBT reduction, when SOD activity was absent. The data were
plotted as the percentage inhibition vs. protein concentration. One unit
of activity was defined as the amount of protein necessary to reduce
the reference rate to 50% of maximum inhibition. The assay mixture
contained catalase to remove H2O2 and diethylenetriaminepenta-
acetic acid (DETAPAC) to chelate metal ions capable of redox cycling
and interference with the assay system. The measurements were
performed spectrophotometrically using a Marcel Media
spectrophotometer (Poland). 
Tissues were homogenized in 0.05 M phosphate buffer (pH 7.8) to
a final concentration of 10%. Homogenates were sonicated and then
centrifuged at 1000 ×g for 15 min (0-4˚C). The supernatant was
drawn and the pellet was discarded. Each supernatant (0.1 ml) was
mixed with 0.8 ml reagent mixture containing: bovine serum albumin
(BSA) in DETAPAC buffer, 50 mM potassium phosphate monobasic
and dibasic buffer, (pH 7.8); 1 mM DETAPAC; 0.13 mg/ml BSA
(12.90 ml); 1.0 U bovine liver catalase (0.5 ml); 5.6×10−5 M NBT
(0.5 ml); 0.1mM xanthine (1.7 ml); 0.05 M potassium phosphate
buffer (0.3 ml); 50.0 μM bathocuproine disulfonate disodium salt
(BCS) (0.1 ml) and 0.1 ml of the xanthine oxidase, 13.2 U/ml to
achieve the required reference rate. All data were expressed in units
of SOD activity per milligram of protein.
Statistical analysis. One-way analysis of variance ANOVA and post-
hoc Tukey test were used to calculate the statistical significance
between groups. Values of SOD activity were assessed by the
nonparametric Mann-Whitney test. Data are represented as the
mean±standard error of the mean.
Results 
Splenic weight. The weight of spleen from leukaemic rats
was increased several fold due to the colonization of
leukaemia cells in this organ in comparison to the healthy
animals. Significant decrease in splenic weight of the rats
was observed when treated with EC at the dose of 40 mg/kg
b.w. both with and without etoposide in comparison to the
control (Figure 1). EC, used at the dose of 20 mg/kg b.w. did
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not influence the splenic weight (Figure 1). Pre-treatment
with EC (40 mg/kg b.w.) followed by co-administration with
etoposide led to a non significant decrease of splenic weight
in comparison to etoposide administration alone. The lower
dose of EC did not influence the spleen weight, changed by
etoposide (Figure 1). 
Cytological evaluation of bone marrow smears. BNML
leukaemia is characterized by slow growth and a strong
suppression of haematopoiesis (23). Cytological studies of
bone marrow were used to compare the effects of EC and
etoposide on the percentage of nucleated erythroid cells,
lymphocytes, monocytes/macrophages and granulocytic
cells. 
Promyelocytes accounted for about 40% of all nucleated
bone marrow cells in the BNML rats, and the percentages of
all normal haematopoietic cells of BNML rats were reduced
in their bone marrow in comparison to the healthy controls
(Table I). 
EC administered to the BNML rats at a dose of 20 mg/kg
b.w. did not significantly influence the percentages of bone
marrow cells, nor did it influence the effect of etoposide in
these cells (Table I). The BNML rats receiving EC at a dose
of 40 mg/kg b.w. exhibited a significant decrease in the
number of promyelocytes by about 62% and increase in the
percentages of normal nucleated erythroid cells, lymphocytes
and macrophages, in comparison to the control group (Table
I). Therefore, the dose of 40 mg/kg b.w. of EC was used for
the subsequent experiments. 
Etoposide administration caused a decrease in cellularity
of the bone marrow. A decrease in the percentage of
promyelocytes by 81% in comparison to the control group
was observed (Table I). 
Co-administration of EC (40 mg/kg b.w.) and etoposide
resulted in further decrease of ~92% in the number of
promyelocytes of total nucleated cells, as compared to the
control, and by 59% compared to etoposide-treated group.
Additionally, EC prevented decrease in the number of normal
nucleated erythroid cells, lymphocytes, granulocytes and
precursors of granulocytes under the influence of etoposide
(Table I).
Influence of the treatment with EC/etoposide on apoptosis
and the percentage of leukaemia cells. Some polyphenols
may enhance antitumor activity of many cytostatics, including
etoposide. Taking into account that EC reveals proapoptotic
activity in leukaemia cells of BNML rats, as shown in our
earlier studies (16), the goal of this study was to compare in
vivo proapoptotic activity of etoposide vs. EC plus etoposide. 
EC reduced the percentage of BNML cells in the spleen
and bone marrow in comparison to the untreated control. A
similar effect was exerted by etoposide. EC significantly
enhanced the effect of etoposide in both examined organs
compared to the group treated with cytostatic only (Figure 2).
EC, and etoposide administration increased significantly
the percentage of annexin-V positive BNML cells both in the
spleen and the bone marrow in comparison to the control
(Figure 3A). EC, when administered both before and with
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Figure 1. Splenic weight of the BNML rats treated with (−)-
epicatechin (EC) and/or etoposide. C, control rats; EC20, rats treated
with EC (20 mg/kg b.w.); EC40, rats treated with EC (40 mg/kg b.w.);
E, rats treated with etoposide (50 mg/kg b.w.); EC20+E, rats treated
with EC (20 mg/kg b.w.) and etoposide (50 mg/kg b.w.); EC40+E, rats
treated with EC (40 mg/kg b.w.) and etoposide (50 mg/kg b.w.). Data
are presented as mean±standard error of the mean. ap<0.05 vs. C;
bp<0.001 vs. C.
Figure 2. The level of leukaemia cells in the spleen and bone marrow. C,
Control rats; EC, rats treated with (−)-epicatechin (EC) (40 mg/kg
b.w.); E, rats treated with etoposide (50 mg/kg b.w.); EC+E, rats treated
with EC (40 mg/kg b.w.) and etoposide (50 mg/kg b.w.). Data are
presented as the mean±standard error of the mean. ap<0.05 vs. C;
bp<0.01 vs. C; cp<0.05 vs. C; dp<0.05 vs. E and EC.
etoposide significantly enhanced the percentage of annexin
V-positive leukaemia cells, both in the spleen and the bone
marrow, in comparison to the treatment with etoposide only
(Figure 3A and B). EC and etoposide also induced necrosis
of leukaemia cells in the bone marrow of the BNML rats;
simultaneous administration of both compounds did not lead
to significant intensification of the process (Figure 3B). 
FRAP. Owing to the fact that EC and etoposide can induce
oxidative damage in myeloid leukaemia cells (17, 18), it can
be assumed that they can affect the antioxidant capacity in
BNML rats. In order to determine the effect of these
compounds on the level of low molecular weight
antioxidants, FRAP analysis was performed. 
EC did not exert a significant effect on the FRAP level in
the liver of healthy rats (110±22 μmol/mg protein) in
comparison to the control (108±25 μmol/mg protein).
However, a significant decrease in FRAP values was
observed under the influence of EC, and etoposide used
separately in rats with leukaemia compared to the control.
The highest significant decrease in FRAP values were
observed in the group of rats that received both EC and
etoposide in comparison to the other groups (Figure 4),
indicating that EC enhances the reduction in defence of the
tissue by the low molecular weight antioxidants caused by
etoposide in the BNML rats.
MDA concentration. Taking into account that apoptosis is
accompanied by an increase in lipid peroxidation, in the next
step, the extent of lipid peroxidation product, MDA, was
assessed.
EC significantly increased MDA levels in BNML rat liver
when compared to the control (Figure 5) but did not induce
such an effect in healthy rats. The level of MDA in healthy
control and healthy EC-treated rats was 0.091±0.01 and
0.095±0.0 nmol/mg protein, respectively. 
MDA concentration was significantly increased under the
influence of etoposide in comparison to the control.
Administration of EC before and with etoposide led to a
significant increase in the MDA level in comparison to
etoposide only (Figure 5), indicating that EC is synergistic
with etoposide in the induction of oxidative stress in the
BNML rats. 
Investigation of SOD activity. SOD is the only defence of the
cells responsible for dismutation of O2•−, therefore
disturbances in its function can favour overproduction of
reactive oxygen species (ROS).
SOD activity was significantly reduced in the EC-treated
BNML rats in comparison to the control (Figure 6).
Etoposide treatment induced a significant increase in the
activity of SOD when compared to the control. When EC
was administered before and with etoposide, a significant
decrease in the SOD activity was observed in comparison to
the rats treated with etoposide only (Figure 6). 
Discussion
Studies by Nakazato et al. (13) have shed light on the
potential new therapeutic strategy of AML treatment by
using ROS-generating agents, such as polyphenol members,
the catechins. These authors have demonstrated that EGCG
intensified the proapoptotic activity of a low concentration
of As2O3 in HL-60 cells by MPO-mediated production of
highly toxic hydroxyl radical. In this article, we present the
first results of studies demonstrating that EC increases the
apoptotic action of etoposide in rat myeloid leukaemia cells,
leading to a significant decrease in the number of these cells.
EC administered from the initial to late stage of the
disease restricted the development of leukaemia. Such an
observation resembles the situation when leukaemia recurs
after remission. These results are in line with our previous
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Table I. Cytology of bone marrow isolated from healthy control and leukaemic rats. H, Healthy control rats; C, control leukaemic rats, EC20, rats
treated with EC (20 mg/kg b.w.); EC40, rats treated with EC (40 mg/kg b.w.); E, leukaemic rats treated with etoposide (50 mg/kg b.w.); EC20+E,
rats treated with EC (20 mg/kg b.w.) and etoposide (50 mg/kg b.w.); EC40+E, rats treated with EC (40 mg/kg b.w.) and etoposide (50 mg/kg b.w.).
Data are presented as the mean percentage of each cell population±standard error of the mean. Means with different letters in the same column differ
significantly, p<0.05. 
Group of rats Promyelocytes Granulocytic Nucleated Lymphocytes Monocytes/
(%) cells (%) erythroid cells (%) (%) macrophages (%)
H 2.0±0.1a 34.3±1.3a 27.6±1.6a 17.0±1.0a 1.9±0.4a
C 37.4±2.2b 67.7±5.2b 10.7±1.3b 5.8±0.6b,c 1.1±0.1a
EC20 31.6±5.8b 63.7±6.6b 13.1±2.1b 6.3±2.1b,c 0.8±0.5a
EC40 14.0±0.5c 48.8±2.6c 20.7±3.7a 12.0±0.1a 2.0±0.0a
E 6.8±0.3d 12.3±2.1d 3.1±0.3c 4.9±1.3b 2.1±0.3a
EC20+E 7.2±0.8d 13.8±1.3d 4.2±2.1c,d 3.9±1.8b 1.6±0.9a
EC40+E 2.6±0.1a 17.2±3.7d 8.8±1.4b,d 9.6±0.7a,c 5.6±1.5b
research which demonstrated the proapoptotic effect of EC
in the same model of rat leukaemia leading to a decrease in
the number of BNML cells (16). 
Cytological evaluation of bone marrow smears proved that
EC leads to a decrease in the proportion of promyelocytes,
with a simultaneous increase of normal bone marrow cells. A
similarly selective activity was shown by EGCG, which
induced apoptosis of a multiple myeloma cell line, without
such an effect on normal activated mononuclear peripheral
blood cells (8). 
It can be supposed that one of the proapoptotic
mechanisms of EC action may be escalating oxidative stress
in leukaemic rats, as evidenced by the significant increase in
MDA level in the liver, one of the target organs for BNML
cells. Other studies have demonstrated that oxidative stress-
induced apoptosis is accompanied by an increase in lipid
oxidation (28). MDA is a product of membrane fatty acid
peroxidation formed under the influence of free radicals (29).
Peroxidation of mitochondrial membrane lipids leads to the
initiation of apoptosis by the release of cytochrome c from
the mitochondrial inner membrane to the cytosol. (28).
However, oxidation of cellular membrane phospholipids may
in turn contribute to the loss of plasma membrane asymmetry
and externalization of phosphatidylserine (30).
FRAP decrease under the influence EC indicates a
reduction in defence of tissue against uncontrolled oxidative
reactions, which in turn results in increased MDA levels. The
observed decrease in SOD activity in the liver could be due
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Figure 3. Apoptosis of leukaemia cells isolated from the BNML rats pre-treated with (−)-epicatechin (EC) followed by coadministration of etoposide.
A: Percentage of annexin V-positive cells. B: Representative dot-plots of annexin V-APC (FL4) vs. 7-AAD (FL3) staining. The cells were isolated from
the spleen of leukaemic rats. C, Leukaemia cells isolated from the control rats; EC, leukaemic cells of rats treated with EC (40 mg/kg b.w.); E,
leukaemic cells of rats treated with etoposide (50 mg/kg b.w.), leukaemic cells of rats treated with EC (40 mg/kg b.w.) and etoposide (50 mg/kg
b.w.). Data are presented as the mean±standard error of the mean. ap<0.05 vs. C; bp<0.001 vs. C; cp<0.01 vs. EC, and E; dp<0.01 vs. E.
to the oxidative damage caused by long-term administration
of a high dose of EC to leukaemic rats.
It should be added that EC did not significantly affect the
MDA levels and FRAP value of healthy rats. Various previous
studies have shown that the pro-oxidative effect of
polyphenols may occur under conditions of increased
oxidative stress, which is found in cancer cells (9, 31). Among
examples of polyphenols which have selective antitumor
activity in cancer cells and have no such action in normal cells
are EGCG and cyanidine 3-rutinozide (9, 31). Cancer cells are
sensitive to pro-oxidative agents that may induce DNA
damage and activate transcription factors sensitive to stress
and which are responsible for cell death (22). 
In our earlier studies, we showed that the BNML rats have
an increased level of oxidative stress in comparison to healthy
animals of the same strain. FRAP values and glutathione level
were significantly reduced; however, expression of heme
oxygenase-1, an enzyme induced by oxidative stress, and
MDA concentrations were significantly higher in the spleen
and brain of BNML rats in comparison to the healthy controls
(32). Additionally, studies of DNA damage by comet assay
showed that the BNML rats also demonstrated elevated
oxidative DNA damage compared to healthy rats, which
correlated with the proportion of leukaemia cells in these rats
(16). Owing to the fact that BNML leukaemia was first
induced with dimethylbenzoanthracene, it can be supposed
that ROS generated by this carcinogen (33) could initiate the
formation of oxidative damage in the BNML cells.
EC as a substrate for MPO may be oxidized to phenoxyl
radicals inducing oxidative stress in the leukaemia cells of
the myeloid lineage. The studies by Galati et al. (34) have
shown that polyphenol-derived pro-oxidative phenoxyl
radicals formed under the influence of MPO may oxidize
lipoproteins, lipids, glutathione and beta-NADH, leading to
the formation of superoxide radical anion. 
Etoposide induced oxidative stress in the BNML rat liver,
as evidenced by a decrease in FRAP values and an increase
in MDA concentration. A significant increase in SOD
activity was observed after the etoposide administration,
which may indicate an increase in defence mechanisms
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Figure 4. Ferric ion reducing ability of plasma (FRAP) values in the
liver of leukaemic rats. C, Control rats; EC, rats treated with (−)-
epicatechin (EC) (40 mg/kg b.w.); E, rats treated with etoposide (50
mg/kg b.w.); EC+E, rats treated with EC (40 mg/kg b.w.) and etoposide
(50 mg/kg b.w.). Data are presented as the mean±standard error of the
mean. ap<0.001 vs. C; bp<0.001 vs. EC; cp<0.05 vs. E.
Figure 5. The level of malondialdehyde (MDA) in the liver of leukaemic
rats. C, Control rats; EC, rats treated with (−)-epicatechin (EC) (40
mg/kg b.w.); E, rats treated with etoposide (50 mg/kg b.w.); EC+E, rats
treated with EC (40 mg/kg b.w.) and etoposide (50 mg/kg b.w.). Data
are presented as the mean±standard error of the mean. ap<0.01 vs. C,
bp<0.001 vs. C, EC, and E.
Figure 6. Superoxide dismutase (SOD) activity in the liver of leukaemic
rats. C, Control rats; EC, rats treated with (−)-epicatechin (EC) (40
mg/kg b.w.); E, rats treated with etoposide (50 mg/kg b.w.); EC+E, rats
treated with EC (40 mg/kg b.w.) and etoposide (50 mg/kg b.w.). Data
are presented as the mean±standard error of the mean. ap<0.05 vs. C
and EC+E, bp<0.001 vs. C, EC, and EC+E.
against excessive production of superoxide anion in the
tissues. Pro-oxidative activity of etoposide correlated with
apoptosis of BNML cells in etoposide-treated rats. 
Detection of phosphatidylserine externalization supported
the fact that EC enhanced the proapoptotic effect of
etoposide in both the investigated organs of leukaemic rats. It
is noteworthy that another catechin, EGCG, sensitized
doxorubicin-resistant leukaemia cells to apoptosis in tumours
of a human carcinoma xenograft model (35). Enhancement
of anticancer action of the etoposide was also observed under
the action of the flavone wogonin, which potentiated the
proapoptotic effect of etoposide in human myeloid leukaemia
HL-60 cells and protected normal rat thymocytes from the
cytotoxic effect of the drug (36). 
Our observations also demonstrate that EC administered
before and with etoposide protected rats against the drastic
decline in normal nucleated erythroid cells and lymphocytes
caused by etoposide. The observed effect is probably due to
the fact that the rats which received EC before etoposide
administration had a higher pool of normal bone marrow
cells in comparison to the animals treated with etoposide
only. It is worth mentioning that the study of Takano et al.
(37) demonstrated the intensification of granulocyte recovery
under the influence of (+)-catechin in rats treated with 5-
fluorouracil, however, the mechanism of this action has not
yet been clarified.
Co-treatment with EC and etoposide caused an increase in
oxidative stress, as shown by a significant increase in MDA
levels and a decrease in FRAP values compared to EC and
etoposide used separately. The reason for the low activity of
SOD in the rats treated with both compounds in comparison
to those treated with etoposide only may be disturbances in
the function of this enzyme under the influence of oxidative
damage induced by EC. Elevated levels of oxidative stress
correlated with apoptosis of BNML cells in the rats co-
treated with EC and etoposide.
The results of this study indicate that EC can modify
etoposide activity, contributing to enhancement of its
anticancer activity in BNML rats. An increase of oxidative
stress by EC appears to be one of the main mechanisms of its
synergistic action with etoposide. The administration of EC
before and with etoposide partially protects against
haemotoxicity caused by etoposide. Therefore, future
investigation of its mechanism of action could be useful for
enhancing the proapoptotic activity of etoposide towards
leukaemia cells while protecting their normal counterparts.
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